Drug-nutrient considerations in patients receiving parenteral and enteral nutrition

Practical Gastroenterology

Volumn 28, Issue 7, 2004, Pages 39-48

  Sacks, Gordon S ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AMIKACIN; AMPHOTERICIN B; AMPICILLIN; BICARBONATE; BUTORPHANOL; CEFAZOLIN; CEFTAZIDIME; CIPROFLOXACIN; CYCLOSPORIN; DIHYDROMORPHINE; DOBUTAMINE; DOPAMINE; DRUG; DRUG METABOLITE; FAMOTIDINE; FENTANYL; GANCICLOVIR; GENTAMICIN; HALOPERIDOL; HEPARIN; INSULIN; LORAZEPAM; MIDAZOLAM; MORPHINE; OFLOXACIN; ONDANSETRON; POTASSIUM DIHYDROGEN PHOSPHATE; RANITIDINE; UNINDEXED DRUG;

ABDOMINAL PAIN; DIARRHEA; DISEASE CLASSIFICATION; DRUG ABSORPTION; DRUG ADMINISTRATION ROUTE; DRUG CLEARANCE; DRUG CONTAMINATION; DRUG DELIVERY SYSTEM; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG DOSAGE FORM; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG FORMULATION; DRUG INCOMPATIBILITY; DRUG METABOLISM; DRUG SAFETY; ENTERIC FEEDING; EX VIVO STUDY; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; HUMAN; METABOLIC DISORDER; NUTRIENT; OUTCOMES RESEARCH; PARENTERAL NUTRITION; PHARMACOKINETICS; PHYSICAL CHEMISTRY; REVIEW; SIDE EFFECT;

EID: 4444284394     PISSN: 02774208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Gauthier I, Malone M. Drug-food interactions in hospitalized patients: methods of prevention. Drug Safety, 1998;18:383-393.
2. Chan L-N. Redefining drug-nutrient interactions. Nutr Clin Pract, 2000;15:249-252.
3. Washington C. The stability of intravenous fat emulsions in total parenteral nutrition mixtures. Int J Pharm, 1990;66:1-21.
4. Food and Drug Administration Safety Alert. Hazards of precipitation associated with parenteral nutrition. Am J Hosp Pharm, 1994;51:1427-1428.
5. Cacek AT, Devito JM, Koonce JR. In vitro evaluation of nasogastric administration methods for phenytoin. Am J Hosp Pharm, 1986;43:689-692.
6. Clark-Schmidt AL, Garnett WR, Lowe DR, et al. Loss of carbamazepine suspension through nasogastric feeding tubes. Am J Hosp Pharm, 1990;47:2034-2037.
7. Healy DP, Brodbeck MC, Clendening CE. Ciprofloxacin absorption is impaired in patients given enteral feedings orally and via gastrostomy and jejunostomy tubes. Antimicrob Agents Chemother, 1996;40:6-10.
8. Mueller BA, Brierton DG, Abel SR, et al. Effect of enteral feeding with Ensure on oral bioavailabilities of ofloxacin and ciprofloxacin. Antimicrob Agents Chemother, 1994;38:2101-2105.
9. Mimoz O, Binter V, Jacolot A, et al. Pharmacokinetics and absolute bioavailability of ciprofloxacin administered through a nasogastric tube with continuous enteral feeding to critically ill patients. Intensive Care Med, 1998;24:1047-1051.
10. Bauer LA. Interference of oral phenytoin absorption by continuous nasogastric feedings. Neurology, 1982;32:570-572.
11. Doak KK, Haas CE, Dunnigan KJ, et al. Bioavailability of phenytoin acid and phenytoin sodium with enteral feedings. Pharmacotherapy, 1998;18:637-645.
12. Chun AH, Shi HH, Achari R, et al. Lansoprazole: administration of the contents of a capsule dosage formulation through a nasogastric tube. Clin Ther, 1996;18:833-842.
13. Phillips JO, Olsen KM, Rebuck JA, et al. A randomized, pharmacokinetic and pharmacodynamic, cross-over study of duodenal or jejunal adminstration compared to nasogastric administration of omeprazole suspension in patients at risk for stress ulcers. Am J Gastroenterol, 2001;96:367-372.
14. Safety briefs. ISMP Medication Safety Alert!, 2002;7(12):1-2.
15. Bailey DG, Malcolm J, Arnold O, et al. Grapefruit juice-drug interactions. Br J Clin Pharmacol, 1998;46:101-110.
16. Chang T, Benet LZ, Hebert MF. The effect of water-soluble vitamin E on cyclosporine pharmacokinetics in healthy volunteers. Clin Pharmacol Ther, 1996;59:297-303.
17. Penrod LE, Allen JB, Cabacungan LR. Warfarin resistance and enteral feedings: two case reports and a supporting in vitro study. Arch Phys Med Rehabil, 2001;82:1270-1273.
18. Petretich DA. Reversal of Osmolite-warfarin interaction by changing warfarin administration time. Clin Pharm, 1990;9:93.
19. Maclaren R, Wachsman BA, Swift DK, et al. Warfarin resistance associated with intravenous lipid administration: discussion of propofol and review of the literature. Pharmacotherapy, 1997;17:133l-1337.
20. Fagan TC, Walle T, Oexmann JM, et al.: Increased clearance of propranolol and theophylline by high-protein compared with high-carbohydrate diet. Clin Pharmacol Ther, 1987;41:402-406.
21. Berlinger WG, Park GD, Specter R. The effect of dietary protein on the clearance of allopurinol and oxypurinol. N Engl J Med, 1985;313:771-776.
22. Mayhew SL, Christensen ML. Pharmacokinetic alterations in malnutrition and obesity. Hasp Pharm, 1993;28:836-837, 840-842, 850.
23. Zarowitz BJ, Pilla LM, Popovich J. Expanded gentamicin volume of distribution in patients with indicators of malnutrition. Clin Pharm, 1990;9:40-44.
24. Sacks GS, Cleary JD. Nutritional impact of lipid-associated amphotericin B formulations. Ann Pharmacother, 1997;31:121-122.
25. Federal Register, 2000;65(17):4103-4111.
26. Miller SJ, Oliver AD. Sorbitol content of selected sugar-free liquid medications. Hosp Pharm, 1993;28:741-744, 755.
27. Lutomski DM, Gora ML, Wright SM, et al. Sorbitol content of selected oral liquids. Ann Pharmacother, 1993;27:269-274.
28. Johnston KR, Govel LA, Andritz MH, et al. Gastrointestinal effects of sorbitol as an additive in liquid medications. Am J Med. 1994;97:185-191.
29. Dickerson RN, Melnik G. Osmolalities of oral drug solutions and suspensions. Am J Hosp Pharm, 1988;45:832-834.
30. Niemiec PW, Vanderveen TW, Morrison JI, et al. Gastrointestinal disorders caused by medications and electrolyte solution osmolality during enteral nutrition. JPEN, 1983;7:387-389.